On September 2, 2021 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, reported that the Company will present at the following upcoming investor conferences (Press release, Fate Therapeutics, SEP 2, 2021, View Source [SID1234587230]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 10:40 am ET
Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 11:00 am ET
H.C. Wainwright 23rd Annual Global Investment Conference available on demand on Monday, September 13 at 7:00 am ET
Baird’s 2021 Global Healthcare Conference on Wednesday, September 15 at 12:15 pm ET
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22 at 4:35 pm ET
2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29 at 10:40 am ET
A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

On September 2, 2021 Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a clinical-stage cell therapy company, reported that it has entered a strategic partnership with OncoBay Clinical to provide comprehensive research support to advance and expand the clinical development program for CHM 1101 (CLTX CAR T) (Press release, Chimeric Therapeutics, SEP 2, 2021, View Source [SID1234587228]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CHM 1101 (CLTX CAR T) is currently being evaluated in a single-site phase 1 clinical trial. This new partnership with OncoBay Clinical will enable the expansion of the program to additional clinical trial sites and aggregate the data from all sites to prepare for the registration phase 2 program. The expansion of this program will take place under Chimeric’s recent IND clearance from the FDA for CHM 1101.

OncoBay Clinical is a first-of-its-kind immuno-oncology CRO specializing in rare and complex oncology indications including cellular therapies. A boutique CRO, OncoBay Clinical is a wholly owned for-profit subsidiary of Moffitt Cancer Center. Through direct partnership, OncoBay Clinical is able to leverage the support of Moffitt’s top scientific advisors, imbedding scientific expertise into every project team and creating "vein-to-vein" control of cell therapy trials.

"OncoBay is a natural partner for us, building upon the cell therapy expertise of our team," said Jennifer Chow, CEO of Chimeric Therapeutics. "With its experience managing the complexity of cell therapy research programs and scientific support from the Moffitt Cancer Center, we believe that the team at OncoBay is uniquely positioned to support the expansion of the CHM 1101 (CLTX CAR T) development program."

"We are excited to be partnering with Chimeric on the development of CHM 1101," said Krystyna Kowalczyk, President and CEO of OncoBay Clinical. "We are confident that our proven ability to succeed in managing the complexities of cell therapy research will enable the accelerated development of Chimeric’s CHM 1101 program."

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

On September 2, 2021 Abbott (NYSE: ABT) reported that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots (Press release, Abbott, SEP 2, 2021, View Source,-LLC [SID1234587224]). Walk Vascular’s peripheral thrombectomy systems will be incorporated into Abbott’s existing endovascular product portfolio. Financial terms were not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott’s ability to provide one-of-a-kind endovascular therapy solutions to improve patient care," said Julie Tyler, senior vice president of Abbott’s vascular business. "Walk Vascular’s technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care."

Walk Vascular’s JETi Peripheral Thrombectomy System and next-generation JETi AIO (All In One) Peripheral Thrombectomy System are unique aspiration systems for the removal of intravascular clots, known as thrombus, that can reduce blood flow and lead to serious complications for patients. The innovative JETi systems are designed to break-up and remove clots from the peripheral vascular system while reducing the risk of dislodged clots. The systems are backed by real-world clinical experiences, and Walk is currently enrolling up to 250 patients in the United States and Europe in the JETi Registry.

Both the JETi Peripheral Thrombectomy Systems have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, as well as CE Mark in Europe and approvals in other countries.

On September 2, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide ("ASO") therapies to address challenging or previously undruggable targets via its LNAplus platform, reported that they have expanded their strategic partnership in the field of ASO-based therapeutics (Press release, Evotec, SEP 2, 2021, View Source;announcements/press-releases/p/evotec-and-secarna-pharmaceuticals-expand-strategic-partnership-in-the-field-of-antisense-drug-discovery-6094 [SID1234587222]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new agreement expands the ongoing successful collaboration between Evotec and Secarna initiated in August 2020. The parties are now also working on industry partners’ discovery, research and development programmes, leveraging Secarna’s industry-leading antisense oligonucleotide expertise with Evotec’s unparalleled discovery and development capabilities.

Dr Craig Johnstone, Chief Operating Officer of Evotec, said: "We are delighted to open our strategic partnership with Secarna for third-party programmes. Secarna’s validated ASO technology provides a highly promising pathway to access targets commonly deemed ‘undruggable’. Leveraging Secarna’s LNAplus technology through the capacity and capabilities of Evotec’s multimodality drug discovery platform will unlock a vast opportunity space for a broad range of partnerships with third parties to develop disease-modifying therapies in indications with high unmet medical need."

Alexander Gebauer, MD, PhD, Chief Executive Officer of Secarna Pharmaceuticals, said: "We are excited to further expand our successful alliance with Evotec. Integrating our proven expertise in the field of antisense discovery into Evotec’s well established discovery and development platform, we form a strong foundation for enabling and strengthening third-party pipelines with our LNAplus ASOs. We are looking forward to continue working with Evotec to make new therapeutic options available to industry partners and the many patients who urgently need them."

On September 2, 2021 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") reported that a study recently published in BMC Cancer shows that blood tests, such as Epi proColon(R), can significantly increase the CRC screening rates in medically underserved populations (MUP) unwilling or unable to complete FIT or colonoscopy. For eligible participants, the rate of testing increased from 12.6% completing a FIT test the previous year to 93.5% with the blood test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Greg Hamilton, CEO of Epigenomics AG, commented: "CRC still is the second leading cause of cancer mortality in the U.S., despite the ability to reduce it through screening. Adherence to regular screening is key to earlier CRC detection thus reducing incidence and mortality. The findings now being published are in line with a series of previously published results that blood tests can make an important contribution to reducing the number of CRC related deaths, especially in medically underserved populations which are the most vulnerable."

In the U.S., many people are not up-to-date with CRC screening despite the available testing, with overall screening rates under 70%. This applies in particular to MUP, who share characteristics such as low income, lack of insurance or being underinsured. Although FIT has desirable characteristics for MUP, return rates are consistently low, around 10% in MUP compared to the general population. This was confirmed in the study now published. In the study, the patients were consecutively offered CRC screening by colonoscopy and FIT, according to the current guidelines for CRC screening. Only when both options were rejected, the blood test was offered. Of the 460 participants ultimately offered screening, no participant accepted the offer of colonoscopy, 30 (6.5%) chose FIT screening and 430 (93.5%) elected for mSEPT9 testing. Only two of the 30 participants who chose FIT returned the test (6.7%).

Hence, the study results show that the introduction of blood-based testing for CRC screening, when compared to FIT, has proven to be well-received by the participants, likely because of convenience and ease of testing. The result is another important contribution to the realization that FDA approved CRC screening blood tests should be incorporated into the screening paradigm, as this is a tangible solution to reduce CRC mortality.